Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Encephalitis D004660 15 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Contracture D003286 3 associated lipids
Stomatitis D013280 14 associated lipids
Weight Loss D015431 56 associated lipids
Endotoxemia D019446 27 associated lipids
Blister D001768 16 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Lupus Nephritis D008181 8 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Ileal Diseases D007077 3 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Gliosis D005911 6 associated lipids
Neuralgia D009437 28 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Amnesia D000647 12 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Sneezing D012912 6 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Liver Failure D017093 5 associated lipids
Hepatitis, Alcoholic D006519 5 associated lipids
Helicobacter Infections D016481 21 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Mucositis D052016 7 associated lipids
Ileitis D007079 2 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Neoplastic Cells, Circulating D009360 5 associated lipids
Corneal Neovascularization D016510 8 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Shock, Cardiogenic D012770 5 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Strongylida Infections D017206 5 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Venous Thrombosis D020246 11 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Larsen GL and Henson PM Mediators of inflammation. 1983 Annu. Rev. Immunol. pmid:6399978
Albert DH and Snyder F Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation. 1983 J. Biol. Chem. pmid:6401298
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Ninio E et al. Biosynthesis of platelet-activating factor (PAF-acether). V. Enhancement of acetyltransferase activity in murine peritoneal cells by calcium ionophore A23187. 1983 Biochim. Biophys. Acta pmid:6405792
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Moschidis MC et al. Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency. 1983 Chem. Phys. Lipids pmid:6627527
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Vargaftig BB et al. Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. 1983 Eur. J. Pharmacol. pmid:6628537
Keraly CL et al. Effect of structural analogues of PAF-acether on platelet desensitization. 1983 Br. J. Haematol. pmid:6824590
Farr RS et al. Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. 1983 Fed. Proc. pmid:6628702
Tence M et al. The enantiomer and the positional isomer of platelet-activating factor. 1983 Biochim. Biophys. Acta pmid:6824744
Denjean A et al. Acute effects of intratracheal administration of platelet-activating factor in baboons. 1983 J Appl Physiol Respir Environ Exerc Physiol pmid:6629917
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Björk J et al. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. 1983 Acta Physiol. Scand. pmid:6659994
Björk J and Smedegård G Acute microvascular effects of PAF-acether, as studied by intravital microscopy. 1983 Eur. J. Pharmacol. pmid:6662199
Yamashita M et al. The metabolism of platelet activating factor in platelets and plasma of various animals. 1983 J Toxicol Sci pmid:6663653
Masugi F et al. [Kidney medulla and hypertension, with special reference to antihypertensive lipids]. 1983 Nihon Jinzo Gakkai Shi pmid:6663856
Tanaka S et al. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs. 1983 J. Pharmacobio-dyn. pmid:6668545
Saeki S et al. Hypotensive activity of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats with various types of hypertension. 1983 Med J Osaka Univ pmid:6669136
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Levy JV Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. 1983 Proc. Soc. Exp. Biol. Med. pmid:6844347
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
O'Flaherty JT et al. Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. 1983 Res. Commun. Chem. Pathol. Pharmacol. pmid:6844746
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397